1. Relationship between the site of esophageal carcinoma and survival of patients with locally advanced disease
Authors: Andrea Masarykova, Ingrid Zavacka, Danijela Scepanovic, Marin Dzongov, Martina Pohrancova, Zuzana Dolinska, Margita Pobijakova
Hospital: Department of Radiation Oncology, National Cancer Institute, Bratislava, Slovakia
OBJECTIVES
METHODS
Background. – In the time of diagnosis esophageal carcinoma is still locally advanced
disease for majority of patients. Different treatment modalities were tried, however, it is
remained disease with poor prognosis and median survival less than 10 months. The adult
human esophagus is an 18- to 25-cm long muscular tube that has cervical, thoracic, and
abdominal parts.
We analyzed relationship between the site of esophageal carcinoma and survival of our
patients with locally advanced disease.
A total of 70 patients with locally advanced esophageal carcinoma
(66 male and 4 female) underwent an radiotherapy (RT) with/without chemotherapy (ChT) or surgery. There were 4 patients who performed only RT, 27 patients concomitant ChT/RT, 19 patients concomitant ChT/RT followed by surgery and 20 patients with concomitant ChT/RT followed by intraluminal brachytherapy (ILBT) during the period from 2008 to Median age was 64 (range, 47-84). Squamous cell esophageal cancer has been represented in 77% patients and a remnant were adenocarcinomas. Eleven patients had carcinoma located in the cervical esophagus, 37 in thoracic and 22 patients in abdominal site of the esophagus.
Graphs and tables
RESULTS
The median follow up for all patients was 16 months (range, 4-108). Locoregional recurrence rate was 6% for patients in the cervical, 9% in thoracic and 6% in abdominal site of disease (p= ). Distant recurrence rate was 6%, 13% and 13% for cervical, thoracic and abdominal site, respectively (p= ). In the group of patients with cervical site of disease only one patient was alive, 5 patients with thoracic site and 5 patients with abdominal site of disease (p= ). The 2- and 3-year overall survival rate for cervical, thoracic and abdominal site was 36% and 9%; 35% and 30%; 36 and 27%, respectively. Only seven of 70 patients showed a long-term survival of longer than 3 years.
CONCLUSIONS
References
Deng HY, Wang WP, Wang YC, et al. Neoadjuvant chemoradiotherapy or chemotherapy? A comprehensive systematic review and meta-analysis of the options for neoadjuvant therapy for treating oesophageal cancer. European Journal of Cardio-Thoracic Surgery 0 (2016) 1–11 doi: /ejcts/ezw315
Markar SR, Noordman BJ, Mackenzie H, et al. Multimodality treatment for esophageal adenocaricnoma: multi-center propensity-score matched study. Annals of Oncology 0: 1–8, 2016
doi: /annonc/mdw560
In conclusion, our study suggests that anatomical site of disease is not significant prognostic factor for survival of the patients with locally advanced esophageal cancer.